Journal article · 2026
A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide
New England Journal of Medicine, 394(6), 529–539 · Published 4 February 2026 · DOI 10.1056/nejmoa2511002
In brief
“A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide” is a 2026 journal article by Ann Marie Navar and 14 co-authors, published in New England Journal of Medicine. OpenAlex counts 77 citations as of 20 November 2026, which puts it in the top 1% of works published in 2026 by citations. The publisher's version is not open access, and OpenAlex records no free legal copy.
- Citations
- 77
- Most cited in
- 2026 (77)
- Field-weighted impact
- 238.48
- References
- 23
- Authors
- 15
Abstract
BACKGROUND: Enlicitide decanoate, an oral proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor, was shown to reduce low-density lipoprotein (LDL) cholesterol levels in a phase 2 trial; longer-term data are needed. METHODS: In this multinational, double-blind, randomized, placebo-controlled trial, we enrolled adults with a history of a major atherosclerotic cardiovascular disease event with an LDL cholesterol… Read the full abstract at the publisher.
Excerpt. This paper is not open access.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Navar, A. M., Mikhailova, E., Catapano, A. L., Banka, P., Blom, D. J., Cadena, A., Kourpanidis, S., Lepor, N. E., Tsukamoto, K., Mendizabal, G., Nunez, J., Zhang, W., Zhu, P., Zhuo, M., & Ballantyne, C. M. (2026). A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide. New England Journal of Medicine, 394(6), 529–539. https://doi.org/10.1056/nejmoa2511002
MLA 9
Navar, Ann Marie, et al. “A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide.” New England Journal of Medicine, vol. 394, no. 6, 2026, pp. 529–539. https://doi.org/10.1056/nejmoa2511002.
Chicago
Navar, Ann Marie, Elina Mikhailova, Alberico Luigi Catapano, Puja Banka, Dirk Jacobus Blom, Alberto Cadena, Susan Kourpanidis, et al. 2026. “A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide.” New England Journal of Medicine 394 (6): 529–539. https://doi.org/10.1056/nejmoa2511002.
Harvard
Navar, A. M. et al. (2026) ‘A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide’, New England Journal of Medicine, 394(6), pp. 529–539. doi:10.1056/nejmoa2511002.
IEEE
A. M. Navar et al., “A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide,” New England Journal of Medicine, vol. 394, no. 6, pp. 529–539, 2026, doi: 10.1056/nejmoa2511002.
BibTeX
@article{navar2026placebo,
title = {{A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide}},
author = {Navar, Ann Marie and Mikhailova, Elina and Catapano, Alberico Luigi and Banka, Puja and Blom, Dirk Jacobus and Cadena, Alberto and Kourpanidis, Susan and Lepor, Norman E. and Tsukamoto, Kazuhisa and Mendizabal, Geraldine and Nunez, Julio and Zhang, Wenjuan and Zhu, Pengfei and Zhuo, Min and Ballantyne, Christie M.},
journal = {New England Journal of Medicine},
year = {2026},
volume = {394},
number = {6},
pages = {529--539},
doi = {10.1056/nejmoa2511002},
url = {https://doi.org/10.1056/nejmoa2511002}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- PCSK9 inhibitors
- LDL cholesterol lowering
- atherosclerotic cardiovascular disease
- hypercholesterolemia
- non-HDL cholesterol
- apolipoprotein B
- lipoprotein(a)
- cardiovascular risk reduction
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Navar, A. M., Mikhailova, E., Catapano, A. L., Banka, P., Blom, D. J., Cadena, A., Kourpanidis, S., Lepor, N. E., Tsukamoto, K., Mendizabal, G., Nunez, J., Zhang, W., Zhu, P., Zhuo, M., & Ballantyne, C. M. (2026). A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide. New England Journal of Medicine, 394(6), 529–539. https://doi.org/10.1056/nejmoa2511002
How many times has this paper been cited?
77 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.
Who wrote this paper?
Ann Marie Navar, Elina Mikhailova, Alberico Luigi Catapano, Puja Banka, Dirk Jacobus Blom, Alberto Cadena, Susan Kourpanidis, Norman E. Lepor, Kazuhisa Tsukamoto, Geraldine Mendizabal, Julio Nunez, Wenjuan Zhang and 3 more.
What is the DOI of this paper?
10.1056/nejmoa2511002, permanently at https://doi.org/10.1056/nejmoa2511002. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.